Lifecore Biomedical, Inc. \De\ (LFCR) — SEC Filings
Lifecore Biomedical, Inc. \De\ (LFCR) — 50 SEC filings. Latest: 8-K (Nov 17, 2025). Includes 32 8-K, 7 SC 13D/A, 4 10-Q.
View Lifecore Biomedical, Inc. \De\ on SEC EDGAR
Overview
Lifecore Biomedical, Inc. \De\ (LFCR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: LIFECORE BIOMEDICAL, INC. reported a net loss of $9.991 million for the three months ended September 30, 2025, an improvement from the $16.230 million net loss in the comparable period ended August 25, 2024. Total revenues increased significantly to $31.109 million, up from $24.705 million in the pr
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Lifecore Biomedical, Inc. \De\ is neutral.
Filing Type Overview
Lifecore Biomedical, Inc. \De\ (LFCR) has filed 32 8-K, 4 10-Q, 3 DEF 14A, 2 10-K, 1 S-1, 7 SC 13D/A, 1 DEFA14A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of LFCR's 49 recent filings, 3 were flagged as high-risk, 24 as medium-risk, and 22 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $31.109M |
| Net Income | -$9.991M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $18.856M |
| Operating Margin | N/A |
| Total Assets | $235.204M |
| Total Debt | $198.418M |
Key Executives
- Thomas D. Salus
- Paul Josephs
- Jason Aryeh
- Christopher S. Kiper
- Ryan D. Lake
- Albert Bolles
- James G. Hall
- Joshua Landes
- Nelson Obus
- Aron R. English
- Beau Garrett
- ARON R. ENGLISH
- BEAU GARRETT
- BRYSON O. HIRAI-HADLEY
- ELAINE THIBODEAU
Industry Context
Lifecore Biomedical operates in the contract development and manufacturing organization (CDMO) sector, serving the pharmaceutical and medical device industries. This sector is characterized by increasing demand for specialized manufacturing capabilities, particularly in aseptic processing. The industry faces competition from both large, established players and smaller, niche providers, with a strong emphasis on regulatory compliance and quality control.
Top Tags
corporate-governance (8) · sec-filing (8) · management-change (6) · financials (4) · material-agreement (4) · filing (4) · shareholder-vote (3) · auditor-change (3) · 8-K (3) · executive-compensation (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $31.109M | Increased from $24.705M in prior comparable period, indicating strong top-line growth. |
| Net Loss | $(9.991)M | Improved from $(16.230)M in prior comparable period, showing progress in loss reduction. |
| Operating Loss | $(3.067)M | Significantly narrowed from $(11.584)M, reflecting improved operational efficiency. |
| Cash and Cash Equivalents | $18.856M | Increased from $8.265M as of May 25, 2025, strengthening liquidity. |
| Property, Plant and Equipment, net | $128.575M | Reflects completion of capacity expansion project, positioning for future growth. |
| Related Party Debt | $129.263M | Substantial debt to related parties, a key financial consideration. |
| Common Stock Outstanding | 37,466,352 | As of October 30, 2025, indicating current share count. |
| Revenue from United States | 60% | Primary geographic revenue source for the three months ended September 30, 2025. |
| Expected Annual Depreciation Increase | $1.6M | Due to completion of capacity expansion project, impacting future profitability. |
| Total Stockholders' (Deficit) Equity | $(10.537)M | Indicates a negative equity position, a financial concern. |
| SEC File Number | 000-27446 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 94-3025618 | Company's tax identification number. |
| Date of 2025 Annual Meeting | October 29, 2025 | Virtual meeting for stockholders |
| Record Date for voting | September 2, 2025 | Determines eligible stockholders for the Annual Meeting |
| Number of directors to be elected | 9 | Includes seven non-Series A Preferred Directors and two Series A Preferred Directors |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Lifecore Biomedical, Inc. \De\ (LFCR)?
Lifecore Biomedical, Inc. \De\ has 50 recent SEC filings from Feb 2024 to Nov 2025, including 32 8-K, 7 SC 13D/A, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LFCR filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Lifecore Biomedical, Inc. \De\ SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lifecore Biomedical, Inc. \De\ (LFCR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lifecore Biomedical, Inc. \De\?
Key financial highlights from Lifecore Biomedical, Inc. \De\'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LFCR?
The investment thesis for LFCR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lifecore Biomedical, Inc. \De\?
Key executives identified across Lifecore Biomedical, Inc. \De\'s filings include Thomas D. Salus, Paul Josephs, Jason Aryeh, Christopher S. Kiper, Ryan D. Lake and 15 others.
What are the main risk factors for Lifecore Biomedical, Inc. \De\ stock?
Of LFCR's 49 assessed filings, 3 were flagged high-risk, 24 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Lifecore Biomedical, Inc. \De\?
Forward guidance and predictions for Lifecore Biomedical, Inc. \De\ are extracted from SEC filings as they are enriched.